Spots Global Cancer Trial Database for Study Evaluating Mitoxantrone in Multiple Sclerosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Mitoxantrone in Multiple Sclerosis
Official Title: A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis
Study ID: NCT00146159
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Berg, , Germany
, Berlin, , Germany
, Düsseldorf, , Germany
, Düsseldorf, , Germany
, Gießen, , Germany
, Marburg, , Germany
, Wiesbaden, , Germany
Contact Details
Name: Medical Monitor
Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
